

Title (en)

ENRICHED AND EXPANDED HUMAN CORD BLOOD STEM CELLS FOR TREATMENT OF HEMATOLOGICAL DISORDERS

Title (de)

ANGEREICHETERTE UND EXPANDIERTE STAMMZELLEN AUS MENSCHLICHEM NABELSCHNURBLUT ZUR BEHANDLUNG VON HÄMATOLOGISCHEN ERKRANKUNGEN

Title (fr)

CELLULES SOUCHES ENRICHIES ET EXPANSÉES DE SANG DE CORDON HUMAIN POUR TRAITEMENT DE TROUBLES HÉMATOLOGIQUES

Publication

EP 2999343 A4 20161228 (EN)

Application

EP 14801860 A 20140516

Priority

- US 201361825354 P 20130520
- US 201461983805 P 20140424
- US 2014038361 W 20140516

Abstract (en)

[origin: WO2014189781A1] This invention relates to an enriched population of isolated and expanded human cord blood stem cells and a method of producing an enriched population of isolated and expanded human cord blood stem cells. The expanded human cord blood stem cells are CD34+, CD90+, CD118+, CD117+, CD49f+, ALDH+, CD45RA- and express pluripotency genes SOX2, OCT4, NANOG, and ZIC3. In one embodiment, the stem cells in the enriched population of the present invention are positive for aldehyde dehydrogenase activity (ALDH+). In addition, in one embodiment the expanded stem cells are nearly depleted of T cells and B cells and contain a limited number of monocytes (CD14). Also disclosed is a method of treating a subject for a hematological disorder using the stem cells of the present invention and a method of determining the effects of a compound on hematopoietic stem cells.

IPC 8 full level

A01N 63/00 (2006.01); **C12N 5/078** (2010.01); **C12N 5/0789** (2010.01); **C12N 15/00** (2006.01)

CPC (source: EP US)

A61P 7/00 (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **C12N 5/0647** (2013.01 - US); **C12N 5/0665** (2013.01 - EP US); **G01N 33/5073** (2013.01 - EP US); **C12N 2500/90** (2013.01 - US); **C12N 2501/065** (2013.01 - EP US); **C12N 2501/999** (2013.01 - EP US)

Citation (search report)

- [YA] US 2011251593 A1 20111013 - KLEIN PETER S [US], et al
- [YA] US 2012301438 A1 20121129 - CHENG LINZHAO [US]
- [XY] ILARIA BURBA ET AL: "Histone Deacetylase Inhibition Enhances Self Renewal and Cardioprotection by Human Cord Blood-Derived CD34+ Cells", PLOS ONE, vol. 6, no. 7, 18 July 2011 (2011-07-18), pages e22158, XP055321088, DOI: 10.1371/journal.pone.0022158 & ILARIA BURBA ET AL: "Materials and Methods S1 Detailed description of experimental procedures of " Histone Deacetylase inhibition enhances self renewal and cardioprotection by human cord blood-derived CD34+ cells", PLOS ONE, 18 July 2011 (2011-07-18), pages e22158, XP055321097, Retrieved from the Internet <URL:http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0022158#pone.0022158.s016> [retrieved on 20161121]
- [A] L. DE FELICE ET AL: "Histone Deacetylase Inhibitor Valproic Acid Enhances the Cytokine-Induced Expansion of Human Hematopoietic Stem Cells", CANCER RESEARCH, vol. 65, no. 4, 15 February 2005 (2005-02-15), US, pages 1505 - 1513, XP055319636, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-04-3063
- [A] J.C. YOUNG ET AL: "Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal", CYTOTHERAPY, vol. 6, no. 4, 1 August 2004 (2004-08-01), GB, pages 328 - 336, XP055321063, ISSN: 1465-3249, DOI: 10.1080/14653240410004899
- [A] STEMCELL: "StemSpan(TM) The Solution to Your Hematopoietic Cell Expansion Needs", 30 November 2012 (2012-11-30), XP055321310, Retrieved from the Internet <URL:https://www.stemcell.com/media/files/brochure/BR28016-StemSpan_The_Solution_Your_Hematopoietic_Cell_Expansion_Needs.pdf> [retrieved on 20161121]
- See references of WO 2014189781A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2014189781 A1 20141127; CA 2912688 A1 20141127; CA 2912688 C 20210713; CN 105705021 A 20160622; CN 105705021 B 20200103; CN 111019894 A 20200417; EP 2999343 A1 20160330; EP 2999343 A4 20161228; JP 2016524468 A 20160818; JP 2019150040 A 20190912; JP 6525963 B2 20190605; US 11261429 B2 20220301; US 2016097036 A1 20160407

DOCDB simple family (application)

US 2014038361 W 20140516; CA 2912688 A 20140516; CN 201480034563 A 20140516; CN 201911214820 A 20140516; EP 14801860 A 20140516; JP 2016514978 A 20140516; JP 2019087708 A 20190507; US 201414892772 A 20140516